Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANSOLYSEN vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pentolinium (ANSOLYSEN) is a ganglionic blocking agent that competitively antagonizes nicotinic acetylcholine receptors at autonomic ganglia, blocking both sympathetic and parasympathetic transmission.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Severe hypertension,Hypertensive crisis
Hypertension
Initial: 2.5 mg intramuscularly or subcutaneously every 6 hours, gradually increased to 5-20 mg every 6 hours as needed.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; may be prolonged to 24-48 hours in renal impairment, necessitating dose adjustment.
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Hepatic metabolism; excreted primarily unchanged in urine.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Renal excretion predominates (approximately 70-80% as unchanged drug via glomerular filtration; remainder as metabolites). Biliary/fecal elimination accounts for <10%.
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
Approximately 30-40% bound to serum albumin; binding is reversible and concentration-independent.
Approximately 70-80% bound to plasma proteins, primarily albumin.
Vd is 0.5-1.0 L/kg indicating extensive tissue distribution (primarily in highly perfused organs), with little accumulation in fat.
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Oral bioavailability is low (10-25%) due to significant first-pass metabolism; subcutaneous bioavailability >90%; intramuscular near 90%; intravenous 100%.
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
Contraindicated in severe renal impairment. For GFR 10-50 m L/min: reduce dose by 50% and increase dosing interval. For GFR <10 m L/min: avoid use.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
No specific guidelines; use with caution in severe hepatic impairment due to potential for increased toxicity.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Not established; safety and efficacy in children have not been determined.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Use with caution; start at lower end of dosing range due to increased sensitivity and risk of hypotension and falls.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
None specified in standard references.
None.
Severe hypotension,Paralytic ileus,Bladder atony,Pupillary dilatation and photophobia,Loss of accommodation,Syncope and precipitating angina,Interstitial pulmonary edema and fibrosis
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Hypersensitivity to pentolinium,Uncooperative patients,Coronary insufficiency,Recent myocardial infarction,Severe renal impairment,Pyloric stenosis,Glaucoma,Bladder neck obstruction,Prostatic hypertrophy
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Avoid tyramine-rich foods (aged cheese, cured meats, fermented products) as ganglionic blockers may potentiate pressor responses. Limit salt intake to manage blood pressure. Grapefruit juice may alter drug metabolism? No known significant interaction; however, general caution with high-tyramine foods is advised.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
First trimester: Potential for teratogenic effects based on animal studies; human data limited. Second and third trimesters: Risk of fetal bradycardia, hypothermia, and respiratory depression due to ganglionic blockade. May cause neonatal hypotension if used near term.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Excretion in human milk unknown; M/P ratio not available. Due to potential for adverse effects in nursing infants (e.g., hypotension, gastrointestinal disturbances), caution advised; consider alternative therapy.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
No specific dosing guidelines; monitor maternal response carefully. Increased volume of distribution may require higher doses, but increased sensitivity may necessitate dose reduction. Use lowest effective dose.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
ANSOLYSEN (mecamylamine) is a secondary amine and a ganglionic blocker used in severe hypertension. Due to its narrow therapeutic index and risk of paralytic ileus, it is rarely used today. Monitor for orthostatic hypotension, urinary retention, and constipation. Avoid in patients with pyloric stenosis, recent myocardial infarction, or glaucoma. Use with caution in renal impairment as drug is renally excreted.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Take exactly as prescribed; do not double doses if missed.,Rise slowly from lying or sitting to prevent dizziness.,Avoid alcohol and hot baths/saunas as they may worsen hypotension.,Report severe constipation, difficulty urinating, or blurred vision immediately.,Do not discontinue abruptly; taper under medical supervision.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANSOLYSEN vs ALDOCLOR-150, answered by our medical review team.
ANSOLYSEN is a Antihypertensive that works by Pentolinium (ANSOLYSEN) is a ganglionic blocking agent that competitively antagonizes nicotinic acetylcholine receptors at autonomic ganglia, blocking both sympathetic and parasympathetic transmission.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANSOLYSEN and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANSOLYSEN is: Initial: 2.5 mg intramuscularly or subcutaneously every 6 hours, gradually increased to 5-20 mg every 6 hours as needed.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANSOLYSEN and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANSOLYSEN is classified as Category C. First trimester: Potential for teratogenic effects based on animal studies; human data limited. Second and third trimesters: Risk of fetal bradycardia, hypothermia, and respiratory. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.